002422 科伦药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.6187.28813.93013.87411.526
总资产报酬率 ROA (%)2.7744.4127.9596.9525.188
投入资产回报率 ROIC (%)3.8486.04610.5118.9576.621

边际利润分析
销售毛利率 (%)47.57047.84651.69352.43052.516
营业利润率 (%)10.15113.61820.29317.03311.530
息税前利润/营业总收入 (%)18.02113.37119.95017.77913.382
净利润/营业总收入 (%)16.13710.14015.41312.3368.952

收益指标分析
经营活动净收益/利润总额(%)46.17186.41092.44488.72087.756
价值变动净收益/利润总额(%)8.2929.9028.51510.43311.821
营业外收支净额/利润总额(%)42.234-4.876-3.289-2.059-6.152

偿债能力分析
流动比率 (X)2.0952.1811.9631.8301.376
速动比率 (X)1.7251.7621.5471.4461.110
资产负债率 (%)28.11226.46228.34736.86650.678
带息债务/全部投入资本 (%)14.34111.25714.87627.32439.040
股东权益/带息债务 (%)572.025752.288545.555255.616151.090
股东权益/负债合计 (%)211.070229.813212.510146.37990.766
利息保障倍数 (X)40.24234.62065.75416.3175.310

营运能力分析
应收账款周转天数 (天)96.36992.05978.21387.082103.975
存货周转天数 (天)149.339142.578130.521124.413130.958